Durbin, Bingaman Push Conflicts Amendment

Good news! Senators Richard Durbin (D-IL) and Jeff Bingaman (D-NM) have introduced an amendment to the prescription drug user fee reauthorization act that would allow just one scientist with a conflict of interest to serve on any Food and Drug Administration advisory panel. Currently, about a quarter of all scientists who serve on these crucial panels have ties to companies whose products are regulated by the agency.

While there's still some behind-the-scenes maneuvering that could keep the amendment away from the full Senate, a vote is expected tomorrow morning.
If you're interested in writing your Senator to support the Durbin-Bingaman amendment to S. 1082, you can find a direct link on this website (click here) or you can send a message through the Center for Science in the Public Interest's "Take Action' website here.